Aleksandra Walewska

Dr. Aleksandra Walewska


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 October 2022 in Antibiotics
Verified
Journal Article
Open access
PDF file
OSOktawian Stachurski
Oktawian Stachurski
DNDamian Neubauer
Damian Neubauer
AWAleksandra Walewska
Aleksandra Walewska
EIEmilia Iłowska
Emilia Iłowska
MBMarta Bauer
Marta Bauer
ESEmilia Sikorska
Emilia Sikorska
This study investigates short cationic antimicrobial lipopeptides composed of 2–4 amino acid residues and C12-C18 fatty acids attached to the N-terminal part of the peptides. The findings were discussed in the context of the relationship among biological activity, self-assembly, stability, and membrane interactions. All the lipopeptides showed the ability to self-assemble in PBS solution. In most cases, the critical aggregation concentration (CAC) much surpassed the minimal inhibitory concentration (MIC) values, suggesting that monomers are the main active form of lipopeptides. The introduction of β-alanine into the peptide sequence resulted in a compound with a high propensity to fibrillate, which increased the peptide stability and activity against S. epidermidis and C. albicans and reduced the cytotoxicity against human keratinocytes. The results of our study indicated that the target of action of lipopeptides is the bacterial membrane. Interestingly, the type of peptide counterion may affect the degree of penetration of the lipid bilayer. In addition, the binding of the lipopeptide to the membrane of Gram-negative bacteria may lead to the release of calcium ions necessary for stabilization of the lipopolysaccharide layer.

Verified
Journal Article
Open access
PDF file
AWAleksandra Walewska
Aleksandra Walewska
PKPaulina Kosikowska-Adamus
Paulina Kosikowska-Adamus
MTMarta Tomczykowska
Marta Tomczykowska
BJBartosz Jaroszewski
Bartosz Jaroszewski
APAdam Prahl
Adam Prahl
GBGrzegorz Bulaj
Grzegorz Bulaj
Human β-defensin 3, HBD-3, is a 45-residue antimicrobial and immunomodulatory peptide that plays multiple roles in the host defense system. In addition to interacting with cell membranes, HBD-3 is also a ligand for melanocortin receptors, cytokine receptors and voltage-gated potassium channels. Structural and functional studies of HBD-3 have been hampered by inefficient synthetic and recombinant expression methods. Herein, we report an optimized Fmoc solid-phase synthesis of this peptide using an orthogonal disulfide bonds formation strategy. Our results suggest that utilization of an optimized resin, coupling reagents and pseudoproline dipeptide building blocks decrease chain aggregation and largely improve the amount of the target peptide in the final crude material, making the synthesis more efficient. We also present an alternative synthesis of HBD-3 in which a replacement of a native disulfide bridge with a diselenide bond improved the oxidative folding. Our work enables further biological and pharmacological characterization of HBD-3, hence advancing our understanding of its therapeutic potential.

Verified
Journal Article
Open access
PDF file
PKPaulina Kosikowska-Adamus
Paulina Kosikowska-Adamus
ESEmilia Sikorska
Emilia Sikorska
DWDariusz Wyrzykowski
Dariusz Wyrzykowski
AWAleksandra Walewska
Aleksandra Walewska
AGAnna Golda
Anna Golda
ALAdam Lesner
Adam Lesner
The alarming raise of multi-drug resistance among human microbial pathogens makes the development of novel therapeutics a priority task. In contrast to conventional antibiotics, antimicrobial peptides (AMPs), besides evoking a broad spectrum of activity against microorganisms, could offer additional benefits, such as the ability to neutralize toxins, modulate inflammatory response, eradicate bacterial and fungal biofilms or prevent their development. The latter properties are of special interest, as most antibiotics available on the market have limited ability to diffuse through rigid structures of biofilms. Lipidation of AMPs is considered as an effective approach for enhancement of their antimicrobial potential and in vivo stability; however, it could also have undesired impact on selectivity, solubility or the aggregation state of the modified peptides. In the present work, we describe the results of structural modifications of compounds designed based on cationic antimicrobial peptides DK5 and CAR-PEG-DK5, derivatized at their N-terminal part with fatty acids with different lengths of carbon chain. The proposed modifications substantially improved antimicrobial properties of the final compounds and their effectiveness in inhibition of biofilm development as well as eradication of pre-formed 24 h old biofilms of Candida albicans and Staphylococcus aureus. The most active compounds (C5-DK5, C12-DK5 and C12-CAR-PEG-DK5) were also potent against multi-drug resistant Staphylococcus aureus USA300 strain and clinical isolates of Pseudomonas aeruginosa. Both experimental and in silico methods revealed strong correlation between the length of fatty acid attached to the peptides and their final membranolytic properties, tendency to self-assemble and cytotoxicity.

10 September 2025 in Biochimica et Biophysica Acta (BBA) - Biomembranes
Verified
Journal Article
Open access
AWAleksandra Walewska
Aleksandra Walewska
PKPaulina Kosikowska-Adamus
Paulina Kosikowska-Adamus
AWAnna Wardowska
Anna Wardowska
GBGrzegorz Bulaj
Grzegorz Bulaj
ESEmilia Sikorska
Emilia Sikorska
Human β-defensins are disulfide-rich peptides that exhibit broad-spectrum antimicrobial activity against bacteria, fungi, and certain viruses, while also exerting immunomodulatory effects. As naturally occurring host defense peptides in the human body, they are less likely to induce adverse immune reactions or toxicity compared to synthetic drugs. Efficient chemical synthesis of cysteine-rich peptides is critical for drug lead optimization studies, yet in many cases is limiting by the low yields of correctly formed disulfide bonds. Herein, we present novel β-defensin 3 analogues with engineered disulfide bonds, designed to simplify and improve oxidative folding while preserving antimicrobial and antifungal activities. Our results suggest that the judicious replacement of cysteine residues with alanines or selenocysteines may facilitate the development of defensin-based drug leads with enhanced pharmacological properties, addressing their therapeutic potential to combat multidrug resistance.

20 November 2025 in Bioorganic Chemistry
Verified
Journal Article
Closed access
AWAleksandra Walewska
Aleksandra Walewska
AWAnna Wardowska
Anna Wardowska
EIEmilia Iłowska
Emilia Iłowska
MMMartyna Misztal
Martyna Misztal
DWDariusz Wyrzykowski
Dariusz Wyrzykowski
ESEmilia Sikorska
Emilia Sikorska